Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause - A Randomized, Double-blind, Placebo-controlled Trial for Improving Sexual Interest and Desire

Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.

开始日期2026-04-01

申办/合作机构

The University of Texas Health Science Center at Houston

NCT07500766

/ Not yet recruiting临床2期IIT

Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Introduction:
Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.
Objective:
To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.
Methods:
This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.
Outcomes:
The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.
Clinical Significance:
This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.
Relevance and Impact:
This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).

开始日期2026-03-01

申办/合作机构

University of Sao Paulo

NCT07143279

/ Recruiting早期临床1期IIT

Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone < 231 ng/dL) male subjects in best supportive care, with no further therapeutic options and no need for resuscitation.
Currently, testosterone formulations for intramuscular (IM) injection and subcutaneous injection as well as for oral and transdermal administration have been approved for androgen therapy. To date, injectable testosterone is the most commonly used formulation. To increase serum testosterone levels to the physiological range IM injections of testosterone every 2-3 weeks are required, which lead to supraphysiological peaks shortly after administration, followed by a sharp fall in levels thereafter. Testosterone levels before the next injection are frequently in the hypogonadal range. For this reason, Sustanon 250® (1 ml, IM) will be administered on day 0 after confirmation of hypogonadism by blood test and then every 15 days in this trial given the limited life expectancy of the subjects and to maximise the effect and benefit of testosterone supplementation.
The Edmonton questionnaire and ADL questionnaire will be completed before the injection on day 0 and then every 15 days at the time of injection until subject's death or if a subject is discontinued from the study treatment/procedures for any other reasons than death. In parallel, the EQ-5D-3L questionnaire will be completed by a family member or a proxy.

开始日期2026-02-11

申办/合作机构

Jules Bordet Institute

100 项与睾酮相关的临床结果

登录后查看更多信息

100 项与睾酮相关的转化医学

登录后查看更多信息

100 项与睾酮相关的专利（医药）

登录后查看更多信息

79,325

项与睾酮相关的文献（医药）

2026-12-31·ANNALS OF HUMAN BIOLOGY

The challenges of optimising the treatment of children diagnosed with idiopathic short stature

Article

作者: Romero, Christopher J. ; Rapaport, Robert

Physicians who treat children with idiopathic short stature (ISS) are challenged in deciding whether the intervention to improve final height is truly efficacious, given the heterogeneity of the diagnosis of ISS. There are numerous studies and reviews that have attempted to assess and demonstrate the benefit of various interventions, such as growth hormone therapy and aromatase inhibitors. Recently, Zhang et al. published a well-written meta-analysis entitled "Comparative effects of growth hormone, testosterone, and aromatase inhibitors on height gain in children and adolescents with idiopathic short statures: a network meta-analysis," attempting to stratify the benefit of several interventions. Our commentary seeks to highlight the importance of more research needed in this field and the complexities of treating children with ISS.

2026-12-31·Aging Male

Vitamin D levels in relation to sexual steroids, sexual function, and quality of life in patients of an andrology outpatient clinic

Article

作者: Haider, Karim Sultan ; Zitzmann, Michael

OBJECTIVE:

This study sought to delineate a putative synergistic interplay between vitamin D and testosterone and their conjoint associations with sexual function and quality of life in men presenting with symptoms of hypogonadism.

METHODS:

A retrospective cohort analysis was performed in men attending the andrological clinic of the University Hospital Münster (Germany) between 2016 and 2021. Individuals exhibited complete biochemical, clinical, and questionnaire datasets. Endocrine parameters, validated psychometric instruments, and demographic variables were systematically evaluated.

RESULTS:

Among 5,324 screened men, 2,059 fulfilled inclusion criteria (mean age 43.9 years). The cohort displayed a pronounced symptom burden (mitigated wellbeing and erectile function). 25-hydroxyvitamin D and testosterone concentrations resided predominantly within suboptimal ranges. Both vitamin D and testosterone correlated inversely with BMI and AMS scores, and positively with IIEF-EF scores (all p < 0.001). Effect size analyses and multiples regressions indicated a robust dependency of symptom severity on vitamin D as well as testosterone status across somatic, sexual, and metabolic indices, underscoring an interdependent relationship between vitamin D and testosterone in shaping sexual function and well-being.

CONCLUSION:

Albeit causality cannot be inferred, this analysis highlights a clinical convergence of vitamin D and testosterone in modulating sexual health and quality of life in men.

2026-12-31·Aging Male

Association between chronic inflammation status and serum testosterone and free testosterone in adult males

Article

作者: Jiao, Yong-zheng ; Meng, Yu-hang ; Qi, Shuai-dang ; Su, Liang ; Wu, Jie ; Zhang, Si-zheng

BACKGROUND:

Chronic inflammation may contribute to biochemical hypogonadism, but evidence regarding composite inflammatory indicators is limited. This study examined the associations of the systemic inflammation response index (SIRI) and aggregate index of systemic inflammation (AISI) with serum testosterone and free testosterone (FT) in adult males.

METHODS:

Data were obtained from NHANES 2011-2016 and 2021-2023, including 7,576 men for serum testosterone and 3,590 for FT. Multivariable regression, smoothing curves, threshold effect, and age-stratified analyses were conducted.

RESULTS:

Higher SIRI and AISI were significantly associated with lower serum testosterone and FT levels (P < 0.0001). Testosterone levels were lowest in the highest quartiles of SIRI and AISI. Nonlinear inverse associations with serum testosterone were observed for both indices, and AISI also showed a nonlinear association with FT, while SIRI showed a linear inverse association. A positive association with biochemical hypogonadism was observed only when defined by serum testosterone. The inverse associations were consistent across all ages for serum testosterone but were evident for FT only in men aged 20-39 and ≥60 years.

CONCLUSION:

SIRI and AISI are independently associated with lower serum testosterone in men, while associations with FT appear age-dependent.

328

项与睾酮相关的新闻（医药）

2026-03-31

·EINPresswire

Testosteronology Society™ Strengthens Clinician Collaboration Through Twice-Weekly Live Grand Rounds

Twice-weekly Grand Rounds enable clinicians to present complex cases live within a multidisciplinary consortium of hormone therapy specialists. FORT LAUDERDALE, FL, UNITED STATES, March 31, 2026 / EINPresswire.com / -- The Testosteronology Society™ is strengthening clinician collaboration through twice-weekly live Grand Rounds, a recurring case-based forum that gives members the opportunity to present difficult testosterone, androgen, and hormone therapy cases for multidisciplinary review and discussion. The program is designed to help clinicians make more informed decisions in challenging situations and improve the care delivered to their patients. Grand Rounds addresses a practical need in hormone-related medicine. Many clinicians encounter patients whose symptoms, lab findings, treatment responses, medication profiles, comorbidities, and mental health variables do not fit neatly into simple treatment frameworks. In these situations, isolated decision-making can lead to uncertainty and inconsistency. The Testosteronology Society™ created Grand Rounds to give members a structured environment where they can bring cases forward, hear different perspectives, and benefit from the shared clinical experience of a diverse professional community. The Society’s Grand Rounds brings together a wide range of medical disciplines that contribute to better testosterone, androgen, and hormone-related care. These include internal medicine, family medicine, naturopathic medicine, functional medicine, pharmacology, women’s health and menopausal medicine, cardiology, infectious disease, emergency medicine, endocrinology, urology, and psychiatry. This multidisciplinary structure is a defining strength of the program because difficult cases often require more than a single-specialty perspective. These twice-weekly sessions are conducted as live Zoom meetings where clinicians from across the United States and internationally can present cases and collaborate in real time across multiple medical disciplines. By creating a place where these perspectives can intersect regularly, the Testosteronology Society™ is helping members think more clearly and act more carefully in the best interest of their patients. Grand Rounds allows clinicians to test clinical reasoning, identify blind spots, compare approaches, and better understand the tradeoffs that shape hormone-related care. The result is stronger education for the clinician and better-informed care for the patient. Thomas O’Connor, M.D., Founder and CEO of the Testosteronology Society™, said the organization was built around the idea that higher standards in hormone care require deeper collaboration across disciplines. “I wanted the Testosteronology Society™ to be the world’s first diverse consortium of healthcare professionals dedicated to providing the highest standard of care for people receiving testosterone, androgens, and other hormone therapies,” said Dr. O’Connor. “This work is bigger than any one doctor or healthcare professional and bigger than any single specialty. It takes multiple disciplines to properly care for people on testosterone, androgens, and hormones.” Testosteronology ® is the clinical foundation of the Testosteronology Society™. It is the Society’s defining medical framework for understanding testosterone, androgens, and hormone-related care through deeper physiology, broader clinical context, and more disciplined reasoning rather than oversimplified treatment models. That foundation supports the Society’s emphasis on multidisciplinary collaboration, careful risk evaluation, individualized care, and a higher standard of decision-making for complex patient presentations. For Society members, the value of Grand Rounds extends beyond the live sessions. The meetings are also recorded, organized, and made searchable as part of the Society’s growing educational resources. This creates an expanding case experience library that members can review as they encounter similar clinical problems in practice. This growing archive adds practical value to the Society’s clinician community and educational mission. It helps members learn not only from their own cases, but also from the collective experience of the Society. When a clinician faces a challenge that is difficult to solve alone, the searchable Grand Rounds archive can provide relevant patterns, decision frameworks, and multidisciplinary insight that support better next steps. “Being part of Testosteronology Grand Rounds has transformed how I approach TRT,” said Stephanie Tobiasz. “The opportunity to discuss complex cases with expert practitioners across a wide range of medical disciplines, share evidence-based protocols, and apply harm-reduction strategies has meaningfully strengthened my practice and the care I provide to patients.” “Attending Testosteronology Grand Rounds equips me with the opportunity to increase my knowledge base and connect with other like-minded healthcare providers who strive to provide the highest standard of care to their patients,” said Jason Bennett, APRN, PMHNP-BC. Steve Sunshine, Chief Operating Officer of the Testosteronology Society™, said the Society views Grand Rounds as an important part of helping clinicians avoid practicing in isolation. “The biggest value of Grand Rounds is that clinicians do not have to work through difficult cases on their own,” said Sunshine. “Our members can present complex cases live in a twice-weekly collaborative setting, hear input from multiple medical disciplines, and continue learning from a growing searchable archive of prior meetings. That combination helps clinicians deliver stronger care and helps patients benefit from broader clinical experience than any one provider could develop alone.” Through twice-weekly live collaboration and a growing recorded case archive, the Testosteronology Society™ continues to build a stronger educational and clinical support system for the medical specialty of Testosteronology ® . About The Testosteronology Society™ The Testosteronology Society™ is a multidisciplinary consortium of healthcare professionals dedicated to advancing the highest standard of care for people receiving testosterone, androgens, and other hormone therapies. Through clinician education, peer collaboration, and twice-weekly Grand Rounds, the Society supports stronger clinical reasoning and improved readiness for complex patient care in the medical specialty of Testosteronology ® . Steve Sunshine Testosteronology Society™ +1 561-441-3642 sunshine@testosteronology.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2026-03-31

·drugs

Intermittent Fasting Might Help Manage Female Hormone Imbalance, Trial Shows

TUESDAY, March 31, 2026 — Intermittent fasting might help manage symptoms from a hormonal condition that affects nearly 1 in 5 women, new clinical trial results say. Weight loss associated with intermittent fasting helped lower testosterone levels in women with polycystic ovary syndrome (PCOS), researchers reported March 27 in the journal Nature Medicine . These lowered levels could wind up improving PCOS symptoms over time, researchers said. “This study and several other studies published by our lab and others show that intermittent fasting can actually improve female hormone levels, particularly in women with PCOS,” researcher Krista Varady , a professor of nutrition at the University of Illinois-Chicago, said in a news release. PCOS occurs when women don’t create enough female hormones needed to ovulate, according to Johns Hopkins Medicine. As a result, the ovaries develop many small fluid-filled sacs called cysts, which produce male hormones like testosterone. Higher levels of these male hormones cause problems like irregular periods, weight gain and infertility among women with PCOS, Johns Hopkins says. “We’re looking for other ways of lowering testosterone levels in these women,” Varady said. “One way is through weight loss. If someone loses around 5% of their body weight, they can actually help lower testosterone levels and sidestep any kind of drug intervention.” Intermittent fasting — restricting eating to a six-to-eight hour daily window — is one potential means of weight loss, but some critics have said the diet might instead disrupt female hormones. “There’s a particular sentiment that intermittent fasting is really bad for women,” Varady said. For the trial, researchers recruited 76 women with PCOS and assigned them to one of three groups. One group adopted intermittent fasting; another tried to lose weight through calorie counting; and the third served as a control group that continued their usual diet. Both fasting and calorie counting cut the women’s food intake by about 200 calories a day, and both groups lost an average 10 pounds during the six-month trial. Both dieting groups also had a decrease in their testosterone levels, researchers said. But only intermittent fasting reduced free androgen index, the ratio between testosterone and the protein that transports it through blood, researchers said. This is a marker of how much active testosterone is reaching a body’s tissues. Intermittent fasting didn’t lessen PCOS symptoms like irregular periods, but researchers said those symptoms might improve with longer time on the diet. About 80% of the women assigned to intermittent fasting said they planned to continue the eating pattern, Varady said. Sources University of Illinois-Chicago, news release, March 27, 2026

2026-03-26

·投医问药

Nature丨多伦多儿童医院/贝勒医学院揭示后颅窝A型室管膜瘤性别差异的机制

点击蓝字关注我们投医问药 Summary 后颅窝A型室管膜瘤是一种罕见的婴儿脑肿瘤，通常被认为由表观遗传机制驱动。与女性患儿相比，男性患儿后颅窝A型室管膜瘤的发病率显著更高、预后更差，但造成这种性别差异的机制至今尚不清楚。该研究旨在解析后颅窝A型室管膜瘤在男性患者中更高发病率和更差预后的生物学基础。 2026年3月25日，多伦多儿童医院和贝勒医学院的研究团队在Nature期刊发表了题为"Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma"（雄激素活性驱动雄性胚胎后脑的致命性后颅窝A型室管膜瘤）的研究论文。研究团队利用四核心基因型小鼠模型证明，雄激素信号而非性染色体延长了雄性小鼠后脑的分化。体外实验表明雄激素补充促进后颅窝A型室管膜瘤生长，而抗雄激素治疗则抑制肿瘤干性潜能和增殖，为这一目前无法治愈的儿童肿瘤提供了新的治疗策略。欢迎关注公众号/设置星标并下载原文 01 ｜INTRODUCTION 室管膜瘤是发生于中枢神经系统各部位的恶性脑肿瘤，目前通过组织学诊断，至少可分类为十种临床和分子特征不同的亚型。最常见的是后颅窝来源的后颅窝A型室管膜瘤，发病年龄中位数约为3岁，缺乏有效化疗且预后最差，五年无进展生存率约为50%。后颅窝A型室管膜瘤与大多数致死性癌症不同，缺乏明确的遗传驱动因素，这阻碍了机制研究和新疗法开发。大多数病例没有已知的体细胞单核苷酸变异或拷贝数变异，1q增益是观察到的最频繁体细胞改变。少数病例存在EZHIP错义突变或也见于弥漫性中线胶质瘤的H3.3 K27M突变。后颅窝A型室管膜瘤表现出CpG高甲基化和低H3K27me3水平，由EZHIP和PRC2抑制剂的表达以及缺氧代谢表型维持。由于后颅窝A型室管膜瘤发生于婴儿和幼儿，推测其起源于仅在子宫内发现的细胞类型，这一观点得到了在后颅窝肿瘤中鉴定早期胚胎细胞类型如胶质生成祖细胞和顶板样干细胞的支持。后颅窝A型室管膜瘤可能在胚胎细胞分化停滞时发生，但除了与PRC2和缺氧的联系外，阻断成熟和驱动转化的机制仍不清楚。多项临床试验显示，后颅窝A型室管膜瘤患儿更可能为男性，且男性患者的生存率显著低于女性。尽管潜在原因尚不清楚，但同年龄段健康儿童的研究表明，女性患儿的小脑神经元转录组似乎比男性更成熟。男性小脑面积比女性大约10%，且男孩小脑体积达到峰值的时间明显晚于女孩（15.6岁 vs 11.8岁）。性别差异在肿瘤发生中已知发挥关键作用，该研究发现揭示了胚胎后脑中雄激素依赖性发育程序解释了男性发病率和预后的偏倚，并强调雄激素信号作为治疗干预的机制基础靶点。 02 ｜RESULTS 研究团队对26例后颅窝A型室管膜瘤原发肿瘤样本进行单细胞RNA测序分析，发现男性患者的无进展生存期显著更差。CancerSEA干性评分在男性患者中显著更高，且男性患者肿瘤中胶质生成祖细胞样细胞比例显著高于女性（54% vs 14%）。Monocle3伪时间轨迹分析显示，男性患者肿瘤细胞在更早期的分化状态聚集。 Kaplan-Meier生存分析证实，具有男性偏倚基因签名的患者总生存期和无进展生存期均显著较差。这些发现首次揭示了后颅窝A型室管膜瘤在男性患者中更具侵袭性的细胞基础。图1. 男性患者后颅窝A型室管膜瘤更具干性且祖细胞样细胞比例更高研究团队构建了胚胎小鼠后脑的全面单细胞图谱，分析了来自8个胚胎时间点（E9-E18）的42万个细胞。鉴定出41种不同的细胞亚群，包括胶质谱系细胞。假时间轨迹分析证实了发育轨迹，女性胶质生成祖细胞富集于翻译起始和RNA代谢通路，而男性胶质生成祖细胞富集于神经前体细胞增殖和胶质生成通路。这些差异表达基因包括Hes1、Sox2、Kit和Bcl7b等，在男性偏倚的后颅窝A型室管膜瘤中也显著上调，揭示了正常发育与肿瘤之间的直接联系。图2. 胚胎小鼠后脑的性别平衡发育转录图谱研究团队将小鼠胶质谱系与后颅窝A型室管膜瘤细胞进行整合分析，发现雄性小鼠肿瘤与早期胶质生成祖细胞和脑室区祖细胞群体更相似。CellRank轨迹推断和Monocle3伪时间分析显示，雄性肿瘤细胞在整个分化过程中保持更像祖细胞的状态。CHETAH层次分类分析证实了显著的细胞类型组成差异，BayesPrism去卷积分析进一步量化了不同细胞类型的比例，揭示了性别的系统性影响。图3. 雄性小鼠后颅窝A型室管膜瘤更类似于胶质生成祖细胞和脑室区祖细胞群研究团队利用四核心基因型小鼠模型解析染色体与性腺的独立效应。该模型包含四种基因型：XXF（雌性性腺的XX小鼠）、XYF（雌性性腺的XY小鼠）、XXM（雄性性腺的XX小鼠）和XYM（雄性性腺的XY小鼠）。E16和E18时间点的通路富集分析显示，有睾丸的小鼠（XXM和XYM）在干细胞群体维持通路中富集，而有卵巢的小鼠则在胶质生成和分化通路中富集。有睾丸小鼠上调的基因（Hes1、Sox2、Kit、Bcl7b、Arid4a）同时也在男性偏倚的后颅窝A型室管膜瘤中上调，证明雄激素而非性染色体是导致男性表型的关键因素。图4. 雄激素在子宫内抑制小脑胶质生成祖细胞分化研究团队对6例后颅窝A型室管膜瘤细胞系进行雄激素处理实验，发现睾酮（50 nM）显著增加克隆形成能力，而雌二醇和孕酮则无效果。Western blot分析显示AR蛋白水平在睾酮或二氢睾酮处理后增加，并发生核转位。极限稀释分析证实睾酮促进所有6例后颅窝A型室管膜瘤细胞系（包括来自女性患者的细胞）的生长，而脊髓室管膜瘤和DIPG细胞对睾酮处理无明显反应，证实了后颅窝A型室管膜瘤对雄激素的特异性响应。图5. 雄激素足以促进后颅窝A型室管膜瘤体外生长 03 ｜DISCUSSION 该研究首次揭示了后颅窝A型室管膜瘤的性别差异生物学机制，证明男性患者更大的脑容量和更高的小脑生长峰值与后脑胶质生成祖细胞分化程序的延长相关。男性人类胎儿在受精后约8周开始产生睾酮，10-20周达到最高水平，新生儿期峰值在出生后1-3个月。这一时间与后颅窝A型室管膜瘤的发病年龄（生命前3年）重叠，提示雄激素在婴儿期持续促进后颅窝A型室管膜瘤细胞生长并阻止分化。该研究证明后颅窝A型室管膜瘤对雄激素信号具有特异性响应，而脊髓室管膜瘤则不响应，为开发抗雄激素治疗策略提供了理论基础。当前后颅窝A型室管膜瘤的标准治疗是最大安全范围手术切除联合放疗，化疗尚无证实疗效。抗雄激素治疗有望成为这一目前无法治愈的儿童肿瘤的新治疗策略，值得进一步开展临床试验验证。 References [1] Kardian AS, Sun H, Ippagunta S et al. Dominant clones leverage developmental epigenomic states to drive ependymoma. Nature 2026. [2] Parker M et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506, 451–455 (2014). [3] Mack SC et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445–450 (2014). [4] Gröbner SN et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018). [5] Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers. Science 363, 1170–1175 (2019). [6] Taylor MD et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8, 323–325 (2005). [7] Johnson RA et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632–636 (2010). [8] Vladoiu MC et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature 572, 67–73 (2019). [9] Panditharatna E, Filbin MG. The growing role of epigenetics in childhood cancers. Curr. Opin. Pediatr. 32, 67–75 (2020). [10] Grünewald TGP et al. Ewing sarcoma. Nat. Rev. Dis. Primers 4, 5 (2018). [11] Barr FG et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 3, 113–117 (1993). 投医问药投医问药起源于清华大学、北京大学和中国科学院，包含投医问药分享会和投医问药俱乐部，以及与清华大学生命科学学院合办的行业大咖论坛等板块，为生物医药领域专业人士专门打造，通过小型圆桌论坛和分享会的形式，提供一个深度交流和合作的平台。俱乐部成员包括PI、博士后、博士生以及生物医药产业和金融界的专业人士。在这里，大家可以分享自己的研究成果，讨论科研转化的可能性，寻找合作伙伴和资本介入的机会。投医问药注重建立信任关系，保持公益性，为生物医药相关人士促成各类资源的精准匹配，促进科研成果、创业想法的转化和社会价值的实现。欢迎关注投医问药，并添加小编微信号：seekmedicine，添加微信时请备注：单位/职业/姓名，如果是PI/教授、创始人、合伙人等，还请注明。声明：本内容仅用作生物医药行业信息传播，不构成任何用药和投资建议。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系seekmedicine@163.com。点赞收藏分享

寡核苷酸

100 项与睾酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00075	睾酮	G03BA03	DB00624

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
继发性睾丸衰竭	美国	Endo Operations Ltd.	2010-12-29
心理性性功能障碍	欧盟	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	欧盟	Teva NI Ltd.	2006-07-28
心理性性功能障碍	冰岛	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	冰岛	Teva NI Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Teva NI Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	挪威	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	挪威	Teva NI Ltd.	2006-07-28
低睾酮水平	美国	Endo Operations Ltd.	2002-10-31
睾酮缺乏	澳大利亚	Teva Pharmaceuticals Australia Pty Ltd	2002-04-10
性腺机能减退	美国	AbbVie, Inc.	1995-09-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性睾丸发育不全综合征	临床3期	美国	Amneal Pharmaceuticals, Inc.	2014-03-01
关节痛	临床3期	美国	Alliance Foundation Trials LLC	2013-09-10
乳腺癌	临床3期	美国	Alliance Foundation Trials LLC	2013-09-10
潮热	临床3期	美国	Alliance Foundation Trials LLC	2013-09-10
肌肉骨骼畸形	临床3期	美国	Alliance Foundation Trials LLC	2013-09-10
阿尔茨海默症	临床3期	美国	Solvay Pharmaceuticals, Inc.	2009-07-01
轻度认知障碍	临床3期	美国	Solvay Pharmaceuticals, Inc.	2009-07-01
无睾症	临床3期	-	Endo Pharmaceuticals, Inc.	2007-08-01
多发性内分泌瘤病	临床3期	-	Abbott Laboratories	2007-02-01
冠心病	临床3期	美国	Abbott Laboratories	2007-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02938923 (STEP-HI, Pubmed \| Obes Pillars)	临床2期	肥胖	66	Exercise + Topical Testosterone Gel	窪築壓餘遞糧製憲壓鏇(鑰築築鏇製壓淵衊憲構) = 鹽壓構艱鹹鹽鬱選餘積醖窪構顧繭網廠積觸範 (顧鏇艱淵餘壓齋夢醖鏇 ) 更多	积极	2026-03-01
				Exercise + Placebo Gel	窪築壓餘遞糧製憲壓鏇(鑰築築鏇製壓淵衊憲構) = 淵艱願鹹憲製淵窪網遞醖窪構顧繭網廠積觸範 (顧鏇艱淵餘壓齋夢醖鏇 ) 更多
NCT03887936 (CTgov)	临床4期	性腺机能减退 \| 2型糖尿病	92	Testosterone gel 1.62% (Testosterone Arm)	餘餘鹹網鹹鑰窪簾鏇廠(獵鏇獵蓋積獵簾獵範構) = 壓膚構廠網艱構鹽鏇積築壓艱餘鏇鹽選製鹹窪 (齋鬱蓋艱構糧製鹹醖網, 8.7) 更多	-	2025-12-23
				Placebo (Placebo Arm)	餘餘鹹網鹹鑰窪簾鏇廠(獵鏇獵蓋積獵簾獵範構) = 繭繭衊繭憲壓齋鑰願築築壓艱餘鏇鹽選製鹹窪 (齋鬱蓋艱構糧製鹹醖網, 11.6) 更多
NCT06154200 (CTgov)	临床2期	干燥综合征 \| 干眼综合征 \| 睑板腺功能障碍	24	Vehicle gel (Vehicle Gel)	餘構鹽醖網網獵鏇鏇鏇(築鹽蓋積積壓顧鏇繭壓) = 製鑰蓋構願夢鏇衊廠餘窪願顧衊網蓋鏇積願艱 (鹹壓餘構積夢築餘夢網, 1.2) 更多	-	2025-05-25
				Testosterone gel 4.5% (Testosterone Gel 4.5%)	餘構鹽醖網網獵鏇鏇鏇(築鹽蓋積積壓顧鏇繭壓) = 襯醖艱構壓壓積選壓遞窪願顧衊網蓋鏇積願艱 (鹹壓餘構積夢築餘夢網, 1.3) 更多
NCT02938923 (STEP-HI, Pubmed \| JAMA Netw Open)	临床3期	髋部骨折	129	Exercise plus Topical Testosterone Gel	繭繭築範選鹽窪構願艱(鏇網衊膚襯膚遞醖鹹夢) = 繭窪構餘繭壓築蓋憲壓鏇鹽遞窪餘憲鹹獵積淵 (壓廠繭製廠構遞觸構鏇, 8.2)	不佳	2025-05-15
				Exercise plus Placebo Gel	繭繭築範選鹽窪構願艱(鏇網衊膚襯膚遞醖鹹夢) = 蓋窪鏇餘糧獵顧觸壓淵鏇鹽遞窪餘憲鹹獵積淵 (壓廠繭製廠構遞觸構鏇, 8.4)
NCT04456296 (CTgov)	临床4期	继发性睾丸衰竭 \| 无睾症	673	AVEED (AVEED® (Testosterone Undecanoate Injection))	醖壓鏇鏇襯廠願廠鹹觸(淵鏇網餘壓壓遞製顧網) = 艱顧襯範觸壓鏇艱齋糧構衊壓糧壓糧壓簾鏇鹽 (簾鏇衊鏇範願窪鏇遞繭, 憲鬱齋顧蓋蓋繭鏇鑰願 ~ 鹽襯構觸衊襯廠餘齋願) 更多	-	2025-03-14
				FORTESTA (FORTESTA® (Testosterone Gel))	醖壓鏇鏇襯廠願廠鹹觸(淵鏇網餘壓壓遞製顧網) = 艱蓋鹹顧憲積鹽鏇繭餘構衊壓糧壓糧壓簾鏇鹽 (簾鏇衊鏇範願窪鏇遞繭, 夢顧獵壓簾蓋鬱壓齋鬱 ~ 壓膚齋糧廠遞膚鏇蓋選) 更多
NCT02432261 (CTgov)	临床1期	-	44	Nestorone® /testosterone gel (Group 1)	蓋齋鹽築簾蓋積範齋選 = 構構憲顧窪鏇築鏇衊膚艱窪廠淵廠壓觸夢廠齋 (鏇鬱醖繭獵製衊選壓鏇, 網製膚餘餘鏇糧餘鏇壓 ~ 積遞鏇醖齋襯鹹簾糧遞) 更多	-	2025-02-13
				Testosterone only gel (Group 2)	蓋齋鹽築簾蓋積範齋選 = 選憲襯顧積鏇鏇積壓蓋艱窪廠淵廠壓觸夢廠齋 (鏇鬱醖繭獵製衊選壓鏇, 鬱膚觸糧範鬱繭獵積選 ~ 淵顧憲構夢鏇鹹醖選醖) 更多
NCT02938923 (STEP-HI, CTgov)	临床3期	髋部骨折 \| 股骨颈骨折 \| 肌肉减少症	129	Testosterone+Supervised exercise training (Exercise + Testosterone (EX + T))	醖憲積憲齋網築艱醖淵(餘蓋觸鹹蓋顧蓋簾鑰鏇) = 遞鬱獵願觸鹹餘製遞遞築窪築壓艱壓蓋糧網壓 (糧夢簾廠廠觸齋構蓋構, 製觸淵鹹網遞製遞選願 ~ 鏇齋鏇醖窪衊夢餘願構) 更多	-	2025-02-04
				Supervised exercise training (Exercise + Placebo (EX + P))	醖憲積憲齋網築艱醖淵(餘蓋觸鹹蓋顧蓋簾鑰鏇) = 顧廠觸顧壓觸窪繭網積築窪築壓艱壓蓋糧網壓 (糧夢簾廠廠觸齋構蓋構, 鏇積鹽鬱選觸淵積蓋糧 ~ 積襯構淵選獵淵積憲鹽) 更多
NCT03518034 (TRAVERSE, CTgov)	临床4期	性腺机能减退 \| 心血管疾病	5,246	AndroGel® (AndroGel 1.62%)	鏇夢獵鹹簾齋構製選繭 = 鹹築願淵襯憲窪製選構鏇艱獵構壓簾鬱淵壓鏇 (簾遞鬱顧淵製選艱獵憲, 糧網願繭簾選艱繭憲鏇 ~ 遞鬱壓鏇願夢築淵憲糧) 更多	-	2024-03-13
				Placebo (Placebo)	鏇夢獵鹹簾齋構製選繭 = 壓顧蓋鏇獵繭製憲製夢鏇艱獵構壓簾鬱淵壓鏇 (簾遞鬱顧淵製選艱獵憲, 齋簾憲繭醖構糧鹽淵壓 ~ 繭獵製範醖鏇鑰鬱餘製) 更多
NCT00467987 (CTgov)	N/A	2型糖尿病 \| 继发性睾丸衰竭 \| 动脉粥样硬化	47	androgel (Androgel)	網夢糧獵鬱淵壓鏇淵淵(壓壓鏇廠遞鑰夢鏇構鹹) = 廠遞膚蓋鹹糧選繭繭糧網廠齋簾鹹繭壓範餘積 (淵鹽顧願鑰鬱夢鑰壓夢, 0.115) 更多	-	2024-02-06
				placebo (Placebo)	網夢糧獵鬱淵壓鏇淵淵(壓壓鏇廠遞鑰夢鏇構鹹) = 製壓網鏇顧壓遞壓憲廠網廠齋簾鹹繭壓範餘積 (淵鹽顧願鑰鬱夢鑰壓夢, 0.127) 更多
NCT03518034 (TRAVERSE, Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床4期	性腺机能减退	5,204	Testosterone gel	選餘築憲憲鹹糧膚窪蓋(憲築鬱網衊構鑰餘製構) = 鑰構醖選鹹餘範築鑰齋鹹鬱鹹糧襯獵鏇製範願 (構構簾廠壓憲餘醖醖選 )	不佳	2024-01-18
				Placebo gel	選餘築憲憲鹹糧膚窪蓋(憲築鬱網衊構鑰餘製構) = 繭蓋願範築鏇憲範壓醖鹹鬱鹹糧襯獵鏇製範願 (構構簾廠壓憲餘醖醖選 )